Article Text

Download PDFPDF
The OUtMATCH study: treating multiple allergies

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

It is recognised that of those children who do have allergies (about 8% of the population), 30–80% have responses to multiple foods. A double blind, placebo-controlled, randomised clinical trial, the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food Allergic Participants (OUtMATCH) study is a three phase study comparing omalizumab to placebo in children with multiple food allergies and is in its first phase. The study then goes on to phase two, a longer-term (52 weeks) treatment with omalizumab with oral immunotherapy and then the third stage will assess the introduction of allergenic foods …

View Full Text


  • Provenance and peer review Commissioned; internally peer reviewed.